MACIVIVA Report Summary
Summary of the context and overall objectives of the project
MACIVIVA stands for “Manufacturing process for Cold-chain Independent Virosome-based Vaccines” and it is an EU Horizon 2020 Consortium (grant agreement No 646122) with a 42 months project involving four European and two Swiss partners that join their expertise for developing new thermostable vaccines. This Consortium brings together skills and competence from well-established Small Medium Enterprises (SMEs) in the field of virosome vaccines, drug formulations, spray drying, immunomonitoring assays, together with world-leading Contract Manufacturing Organizations (CMOs) with large scale manufacturing, freeze drying expertise, and packaging capabilities.
Click here to read the full report
Summary of the context and overall objectives of the project
MACIVIVA stands for “Manufacturing process for Cold-chain Independent Virosome-based Vaccines” and it is an EU Horizon 2020 Consortium (grant agreement No 646122) with a 42 months project involving four European and two Swiss partners that join their expertise for developing new thermostable vaccines. This Consortium brings together skills and competence from well-established Small Medium Enterprises (SMEs) in the field of virosome vaccines, drug formulations, spray drying, immunomonitoring assays, together with world-leading Contract Manufacturing Organizations (CMOs) with large scale manufacturing, freeze drying expertise, and packaging capabilities.